Latest news with #OADs

Time of India

Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India

Emcure Pharmaceuticals Ltd and Sanofi India Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India with immediate effect. Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement. Explore courses from Top Institutes in Select a Course Category Operations Management Data Analytics Finance Data Science Artificial Intelligence MBA Product Management PGDM Technology Project Management Healthcare Cybersecurity Public Policy Degree MCA Leadership Management CXO Others Digital Marketing healthcare others Design Thinking Data Science Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hörspezialisten verlieren Kunden: Dieses 89€-Gerät spricht sich herum Top Trending News Today Mehr erfahren Undo "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them," Emcure Pharmaceuticals CEO and MD Satish Mehta said. Further, he said, "This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country." Live Events Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, "With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them." The two companies said there would be no people transition from Sanofi India to Emcure under their distribution and promotion agreement.